Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.58 |
| ▸ | FEN1 | P39748 | 1/20 | 0.58 |
| ▸ | CES2 | O00748 | 3/20 | 0.58 |
| ▸ | CES1 | P23141 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.50 |
| ▸ | WNT3A | P56704 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30301349 | 0.98 | PTPN1 (0.56) | PTPN1ERCC5FEN1CES2CES1 | |
| Hydrochloric Acid SCHEMBL1653086 | 0.98 | PTPN1 (0.56) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL27533876 | 0.84 | ALDH1A1 (0.46) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL30839516 | 0.83 | CES2 (0.61) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL14404518 | 0.83 | CES2 (0.61) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL30089515 | 0.82 | CTNNB1 (0.68) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL20508992 | 0.82 | PTPN1 (0.74) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL167448 | 0.80 | CES2 (0.60) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL14732971 | 0.80 | CTNNB1 (0.61) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL8343202 | 0.80 | CES2 (0.60) | PTPN1ERCC5FEN1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| EP-3581572-B1 | ADENOSINE A3 RECEPTOR MODULATORS | PALOBIOFARMA SL (ES) | 2020-11-25 | — | — | EP | disclosed |
| WO-2018134464-A1 | ADENOSINE A3 RECEPTOR MODULATORS | PALOBIOFARMA, S.L. (ES) | 2018-07-26 | — | — | WO | disclosed |
| CN-104628646-A | N-pyrazolyl formanilide compound, intermediate, composition, preparation method and application | SHANGHAI INSITITUTE OF ORGANIC CHEMISTRY CHINESE ACADEMY OF SCIENCES | 2015-05-20 | — | — | CN | disclosed |
| US-8993570-B2 | Substituted triazolo-pyridazine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8501738-B2 | Substituted triazolo-pyridazine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110065711-A1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| EP-0143711-B1 | DERIVATIVES OF N-(METHOXYPHENACYL)AMINE, THEIR THERAPEUTICAL USE AND PROCESS FOR THEIR PREPARATION | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1987-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065711-A1 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | GABRA5, GABRA2, GABRA3 | PTPN1 1444/4885ERCC5 3914/4885FEN1 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.